SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intuitive Machines, Inc. is a space exploration, infrastructure, and services company, which engages in contributing to the establishment of cislunar infrastructure and helping to develop cislunar and deep space commerce. It offers space products and services. The company was founded by Stephen J. Altemus, Kam Ghaffarian, and Timothy P. Crain in 2013 and is headquartered in Houston, TX.

Intuitive Machines Inc - Ordinary Shares - Class A

Intuitive Machines Inc

Intuitive Machines is trending after a $175 million private equity placement caused an initial stock drop, with the community actively debating whether the dilution is an overreaction or a strategic move that provides capital for significant growth initiatives and positions the company for anticipated NASA contracts.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle is trending after a substantial Q4 earnings beat, driven by surging USDC adoption and revenue, which has ignited bullish enthusiasm for its future potential and a potential short squeeze, while some investors remain wary of regulatory hurdles and valuation.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is a prominent trending topic, fueled by strong community conviction in its innovative cancer therapy, Anktiva, which is driving a belief in an impending short squeeze amid high short interest and anticipation of upcoming regulatory milestones and clinical updates.

Oddity Tech Ltd. engages in the online retail sale of cosmetics and beauty products. Its products include lipsticks, makeup brushes, mascara, eyelash curlers, and makeup brush cleansers. The company was founded by Oran Holtzman and Shiran Holtzman-Erel on March 23, 2013 and is headquartered in Tel Aviv, Israel.

ODDITY Tech Ltd. - Ordinary Shares - Class A

ODDITY Tech is experiencing extreme volatility following revised guidance that anticipates a significant near-term revenue decline due to issues with acquisition costs and algorithm changes. This has ignited a fierce debate within the community, with many investors seeing a deep value opportunity given the company's cash reserves and buyback plan, while others voice concerns over the business outlook and allegations from a recent short report.

Larimar Therapeutics, Inc. Is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics mitochondrial disorders and Friedreich's ataxia. The company was founded in 2005 and is headquartered in Bala Cynwyd, PA.

Larimar Therapeutics Inc

Larimar Therapeutics is soaring after its nomlabofusp program received FDA Breakthrough Therapy Designation for Friedreich's ataxia, fueling significant community excitement around its potential for accelerated approval and driving speculation of high price targets and a possible big pharma buyout.

Cava Group, Inc. is a holding company, which engages in the category-defining Mediterranean fast-casual restaurant brand, bringing together healthful food and bold, satisfying flavors at scale. It operates through the following segments: CAVA and CAVA Foods. The CAVA segment includes the operations of all company-owned CAVA restaurants. The CAVA Foods segment includes the production of dips and spreads used in CAVA restaurants as well as sales from the consumer-packaged goods (CPG) business. The company was founded by Brett Schulman, Ike Grigoropoulus, Dimitri Moshovitis, and Theodore Xenohristos in 2010 and is headquartered in Washington, DC.

Cava Group Inc

CAVA Group Inc

CAVA is surging after delivering strong earnings and an optimistic fiscal outlook, fueling bullish sentiment around its expansion and triggering a short squeeze. The community is sharply divided, with bulls emphasizing growth potential and analyst upgrades, while bears caution against its high valuation and mixed underlying fundamentals compared to competitors like Chipotle.

Workday, Inc. engages in the provision of development of enterprise cloud applications for finance and human resources. It delivers financial management, human capital management and analytics applications designed for companies, educational institutions, and government agencies. The company was founded by David A. Duffield and Aneel Bhusri in 2005 and is headquartered in Pleasanton, CA.

Workday Inc - Ordinary Shares - Class A

Workday Inc

Workday is experiencing a sharp sell-off despite beating Q4 earnings estimates, as investors grapple with the company's fiscal 2027 outlook and intensified debate over AI's potential disruption to the broader enterprise software sector.

Navitas Semiconductor Corp. engages in the development of ultra-efficient gallium nitride (GaN) semiconductors. Its GaN power ICs integrate GaN power with drive, control and protection to enable charging, power density, and energy savings for mobile, consumer, enterprise, eMobility and new energy markets. The company was founded by Daniel Kinzer, Nick Fichtenbaum, Gene Sheridan, and Jason Zhang on August 12, 2020 and is headquartered in Torrance, CA.

Navitas Semiconductor Corp

Navitas Semiconductor is trending as the community debates its innovative GaN and SiC power platforms for next-gen AI data centers and grid infrastructure, with optimism for future contracts from hyperscalers like NVIDIA clashing against concerns over recent revenue declines and the current absence of major, confirmed orders.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is the focus of intense market discussion ahead of its impending earnings report, with widespread anticipation that its results will heavily influence the direction of the broader AI and tech sectors. Community sentiment is sharply divided, speculating whether a likely earnings beat will propel the stock to new highs or lead to a "sell the news" event, compounded by high options volatility.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is generating buzz with its aggressive deployment of institutional privacy features via EY Nightfall and a new Web2-to-Web3 SDK (Starkzap), alongside rising DeFi metrics and strategic cross-chain expansions to Solana, solidifying its position as a technically advanced, long-term infrastructure play for a quantum-resistant and scalable future.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>TeraWulf is expected to report fourth-quarter revenue of $44.1 million, according to data from fiscal.ai. The company in the same quarter last year reported a revenue of $35 million.&nbsp;</li><li>A user on Stocktwits predicted that the stock will cross $30 post its earnings because of WULF’s growth in energy and data centers.&nbsp;</li><li>TeraWulf has been pivoting aggressively from Bitcoin mining toward high-performance computing and AI data center hosting.&nbsp;</li></ul>Shares of TeraWulf rallied 10% on Tuesday as investors eagerly await its quarterly earnings that are expected to come this week.&nbsp;At the time of writing, stock was up 13% at $17.74.&nbsp;<h2 class="st-heading-2">What Is Retail Thinking?</h2>Retail sentiment around WULF trended in ‘neutral’ territory amid ‘low’ message volume.&nbsp;One bullish user said that if bitcoin is believed to be at $150,000 levels, then WULF stock can reach $60 by the end of 2026.&nbsp;<stembedurl>https://stocktwits.com/zingman/message/645741240</stembedurl>Another bullish user said that they wished to have 100 times more WULF shares than they currently own.&nbsp;<stembedurl>https://stocktwits.com/AllMarkets/message/645735377</stembedurl>Yet&nbsp;another user predicted that the stock will cross $30 post its earnings because of WULF’s growth in energy and data centers.&nbsp;<stembedurl>https://stocktwits.com/jam324/message/645735138</stembedurl><h2 class="st-heading-2">Q4 Earnings Preview</h2>TeraWulf is expected to report fourth-quarter revenue of $44.1 million, according to data from fiscal.ai. The company in the same quarter last year reported a revenue of $35 million.&nbsp;The company is also expected to post a higher loss of $0.14 per share in the fourth quarter compared to a loss per share of $0.08 in the same quarter last year.&nbsp;<h2 class="st-heading-2">Company’s Move To AI/HPC</h2>TeraWulf has been&nbsp; pivoting aggressively from Bitcoin mining toward high-performance computing (HPC) and AI data center hosting. Earlier in the month, it announced that it is expanding its digital and power infrastructure portfolio.The company said it is expanding its portfolio through the acquisition of two strategically located brownfield infrastructure sites in Hawesville, Kentucky and Charles County, Maryland.TeraWulf’s infrastructure portfolio now totals approximately 2.8 GW across five sites, including 642.5 MW of contracted capacity and 2.2 GW of owned pipeline capacity.This expanded development pipeline supports its growth strategy targeting 250 to 500 MW of new contracted capacity annually, aligned with customer demand, power availability, and regional grid conditions.WULF stock has rallied more than 300%&nbsp;over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

 In this photo illustration, the TeraWulf (Tera Wulf) logo is seen displayed on a smartphone screen.

Terawulf Stock Is Up 10% But Retail Still Sees More Than 250% Upside: Here’s Why

Analysts expect the company to post higher fourth quarter revenue than the year-ago quarter, as per data from fiscal.ai. 

Equity

Analysts expect the company to post higher fourth quarter revenue than the year-ago quarter, as per data from fiscal.ai. 


Should Schwab U.S. Small-Cap ETF (SCHA) Be on Your Investing Radar?

<ul class="summary-bullets"><li>Wealth-management stocks slid on Tuesday after tech platform Altruist introduced an AI-powered tax planning tool.</li><li>Wurster said the selloff left him “disappointed and surprised” because he believes that AI would strengthen advisers’ capabilities.</li><li>Schwab is well-positioned to benefit from AI due to its scale and extensive data, Wurster added.</li></ul>Charles Schwab (SCHW) CEO Rick Wurster pushed back against growing concerns that artificial intelligence could disrupt the wealth management industry, arguing instead that the technology will enhance adviser productivity.Wurster emphasized that AI should be viewed as a supportive tool rather than a replacement for human expertise, according to a Bloomberg interview on Wednesday. “With the power of AI, not only are we reaching those clients we have a relationship with, we are able to help a whole new group of clients,” Wurst said.His comments came after a selloff that dragged down shares of several wealth-management firms following the launch of Altruist’s AI-powered tax planning tool on Tuesday.<a href="https://stocktwits.com/symbol/SCHW">SCHW stock</a> was down 3% in morning trade after closing over 7% lower in the previous session.<h2 class="st-heading-2">Altruist’s AI Tool Leads To Selloff</h2>Wealth-management stocks slid on Tuesday after tech platform Altruist introduced an AI-powered tax planning tool within its Hazel platform, raising concerns about pressure on traditional advisory services. Shares of Raymond James Financial fell over 8%, while Stifel Financial declined around 4% on Tuesday.The tool analyzes client financial data to create personalized tax strategies, aiming to improve outcomes and efficiency. Altruist added that strict zero data-retention agreements ensure customer information is not stored or used to train AI models.<h2 class="st-heading-2">Wurster Says He Is Disappointed And Surprised By Recent Selloff</h2>Wurster said the decline in the brokerage’s shares left him “disappointed and surprised” because he believes that artificial intelligence would strengthen advisers’ capabilities rather than replace them.“The market is missing that we are a natural winner in the AI space because of all of the advantages we have — because of our size, our scale, our data,” he said.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment shifted to ‘bullish’ from ‘bearish’ a day earlier, amid ‘extremely high’ message volumes.<img src="https://news.stocktwits-cdn.com/SCHW_jpg_af0628c78b.webp" alt="SCHW.jpg">However, some users expressed concerns about the company’s future amid the “AI onslaught”.<stembedurl>https://stocktwits.com/Free43ver/message/644650446</stembedurl><stembedurl>https://stocktwits.com/Mahaperrotta/message/644618898</stembedurl>SCHW stock has shed over 3% so far in 2026.was up 1.6% in pre-market trading after closing over 7% lower in the previous session.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/khc-stock-slumps-weak-q4-results-pauses-separation/cZb6X4CR4qY">Kraft Heinz Pauses Separation Plan Amid Weak Q4 Print – KHC Stock Slumps 7% Pre-Market</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Charles Schwab company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Charles Schwab CEO Reportedly Explains Why AI Won’t Disrupt Wealth Management Industry: ‘We Are Able To Help A Whole New Group Of Clients’

CEO Rick Wurster said that AI should be viewed as a supportive tool rather than a replacement for human expertise, according to an interview with Bloomberg on Wednesday.

Will the Ongoing Market Rally Continue in 2026? ETFs in Focus

S&P 500 momentum and retail inflows set the stage for a potential 2026 rally, with ETFs offering ways to ride the bullish trend.

More Fed Rate Cuts in 2026? ETFs to Play the Opportunities

Softer inflation and dovish signals point to more 2026 rate cuts. These ETFs can help investors ride potential gains.

ETFs to Benefit From Rate Cut Bets and Upbeat Forecasts

ETFs to watch as Wall Street turns upbeat, with bullish forecasts putting the S&P 500 on track for 8,000 by 2026.

<ul class="summary-bullets"><li>Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with semaglutide.</li><li>The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026. &nbsp;</li></ul>Neumora Therapeutics, Inc. (NMRA) on Monday announced positive data from preclinical studies for its experimental weight-loss therapy NMRA-215.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174401/0/en/Neumora-Therapeutics-Announces-Class-Leading-Weight-Loss-Demonstrated-with-NMRA-215-in-Preclinical-Diet-Induced-Obesity-Model.html">said</a> that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide in mice with diet-induced obesity. Semaglutide is the active ingredient in Novo Nordisk’s (NVO) popular weight-loss drug Wegovy.<h2 class="st-heading-2">Plans Ahead</h2>NMRA-215 is an oral NLRP3 inhibitor in development for the treatment of obesity. It blocks the activity of the NLRP3 inflammasome, a protein complex involved in the immune response to inflammation. NLRP3-mediated neuroinflammation in the hypothalamus is linked to obesity, Neumora noted.The company now plans to initiate an early-stage clinical study for the experimental drug in the first quarter of 2026.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Shares of the company jumped about 22% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NMRA">NMRA stock</a> stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<blockquote>“These data demonstrate NMRA-215 drives meaningful weight loss as a monotherapy in mice, including incretin-like induction, additive weight loss in the combination setting with semaglutide, as well as the potential to enable incretin-sparing dosing regimens.” – Paul Berns, CEO, Neumora Therapeutics</blockquote>Separately, Neumora on Monday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/27/3174424/0/en/Neumora-Therapeutics-Announces-Initiation-of-Phase-1-Clinical-Study-of-M4-Positive-Allosteric-Modulator-NMRA-898.html">announced</a> the initiation of an early-stage study of its NMRA-898 aimed at evaluating safety, tolerability, and human pharmacokinetic data of the compound for potential use in the treatment of schizophrenia and other neuropsychiatric disorders.&nbsp;NMRA stock is down by 75% this year and by about 78% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/eth-outperforms-btc-as-retail-sentiment-improves-ahead-of-fed-rate-decision/cLG030ZR3Mh">Ethereum Outperforms Bitcoin As Retail Sentiment Improves Ahead Of Fed Rate Decision, Trump-Xi Meeting This Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Neumora Therapeutics’ Experimental Drug Demonstrates Weight Loss in Preclinical Studies

Neumora said that NMRA-215 demonstrated weight loss of up to 19% as a monotherapy and 26% in combination with Semaglutide.

Shares of Alto Neuroscience (ANRO) soared 54% on Friday afternoon after the company announced that the U.S. Food and Drug Administration granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia.Cognitive impairment is a core and disabling feature of Schizophrenia, a serious, disabling mental illness affecting thought, perception, and behavior. According to Alto, there are currently no approved treatments for cognitive impairment associated with schizophrenia.FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. A company, whose drug has a Fast Track designation, may be eligible for more frequent meetings with the FDA to discuss the drug’s development plan, as well as for accelerated approval and priority review, subject to the fulfillment of relevant criteria.ALTO-101 is an inhibitor of the PDE4 enzyme that plays a key role in the brain by breaking down a molecule fundamental to learning and memory. By inhibiting the enzyme, the drug seeks to increase the levels of the molecule believed to improve cognitive function.Alto CEO Amit Etkin <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.altoneuroscience.com/news/news-details/2025/Alto-Neuroscience-Receives-FDA-Fast-Track-Designation-for-ALTO-101-for-the-Treatment-of-Cognitive-Impairment-Associated-with-Schizophrenia/default.aspx">termed</a> the designation a significant milestone. “Our Phase 1 data, which demonstrated significant and clinically relevant effects of ALTO-101 on both EEG measures and cognitive performance in healthy subjects, provides strong validation for its mechanism,” he added.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ANRO">ANRO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:579/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_03_at_12_01_14_PM_png_f2a3fffa4a.webp" alt="ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits" width="579" height="59"><figcaption>ANRO's Sentiment Meter and Message Volume as of 12 p.m. ET on Oct. 03, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user highlighted the company’s strong pipeline. Alto is seeking to develop treatments for mental health conditions, including bipolar depression, major depressive disorder, treatment-resistant depression (TRD), and schizophrenia.<stembedurl>https://stocktwits.com/Ccperk/message/630959482</stembedurl>Another user believes the FDA's Fast Track designation is the icing on the cake.<stembedurl>https://stocktwits.com/Ccperk/message/630949029</stembedurl>ANRO stock is up by 61% this year but down by 33% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-reportedly-eyes-door-redesign-to-alleviate-safety-concerns-report/chCuVXzR3QQ">Rivian Reportedly Eyes Door Redesign To Alleviate Safety Concerns: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alto Neuroscience logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug

FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need.

ETFs to Ride the Small-Cap Comeback Wave 

Rate cut hopes and investor rotation beyond tech are fueling renewed momentum in small-cap stocks, with the Russell 2000 surging in August.

Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

Ahead of earnings, sentiment is split between blowout AI growth and concerns around macro pressure, positioning, and post-ER volatility. How do you see it playing out?

Current Price	$30.53
Prev Close	$30.65
Open	$30.78
Dividend Yield	N/A
50-Day Moving Average	$29.96
Beta	N/A
Avg. Volume	3.27M
PE Ratio	N/A

52-Week High	$31.25
52-Week Low	$20.04
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A

SCHA
Schwab Strategic Trust - Schwab U.S. Small-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest SCHA News

SCHASchwab Strategic Trust - Schwab U.S. Small-Cap ETF